JÃ¼rgen Behr

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6774743/publications.pdf

Version: 2024-02-01

		87723	14156
151	17,431	38	128
papers	citations	h-index	g-index

155	155	155	12142
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 788-824.	2.5	6,033
2	Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2018, 198, e44-e68.	2.5	2,678
3	An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2015, 192, e3-e19.	2.5	1,521
4	Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 265-275.	2.5	1,006
5	BUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 92-99.	2.5	497
6	Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan. Annals of Internal Medicine, 2013, 158, 641.	2.0	437
7	Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. European Respiratory Journal, 2015, 46, 1113-1130.	3.1	328
8	Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. Journal of the American College of Cardiology, 2004, 43, 764-770.	1.2	266
9	Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respiratory Medicine,the, 2021, 9, 476-486.	5.2	254
10	Inhaled Iloprost To Treat Severe Pulmonary Hypertension: An Uncontrolled Trial. Annals of Internal Medicine, 2000, 132, 435.	2.0	229
11	Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2018, 379, 1722-1731.	13.9	207
12	Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. European Respiratory Journal, 2015, 46, 186-196.	3.1	194
13	A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1249-1254.	2.5	166
14	Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study. Lancet Respiratory Medicine,the, 2019, 7, 780-790.	5.2	139
15	Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. Respiratory Research, 2017, 18, 139.	1.4	135
16	Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial. European Respiratory Journal, 2013, 41, 853-860.	3.1	130
17	Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction. European Respiratory Journal, 2015, 46, 1370-1377.	3.1	129
18	Increased Extracellular Vesicles Mediate WNT5A Signaling in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1527-1538.	2.5	127

#	Article	IF	Citations
19	Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respiratory Medicine,the, 2016, 4, 445-453.	5.2	108
20	Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. Journal of Heart and Lung Transplantation, 2020, 39, 1435-1444.	0.3	104
21	Acute Exacerbation in Interstitial Lung Disease. Frontiers in Medicine, 2017, 4, 176.	1.2	101
22	Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respiratory Medicine,the, 2021, 9, 85-95.	5.2	96
23	Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial. BMC Pulmonary Medicine, 2017, 17, 122.	0.8	94
24	Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 199-208.	2.5	90
25	Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias. PLoS ONE, 2015, 10, e0141911.	1.1	80
26	FK506-Binding Protein 10, a Potential Novel Drug Target for Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 455-467.	2.5	80
27	Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international caseâ€“cohort study. European Respiratory Journal, 2017, 50, 1700936.	3.1	75
28	Lung Deposition of a Liposomal Cyclosporine A Inhalation Solution in Patients after Lung Transplantation. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2009, 22, 121-130.	0.7	62
29	Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation. European Respiratory Journal, 2020, 55, 1901760.	3.1	61
30	Core Muscle Size Predicts Postoperative Outcome in Lung Transplant Candidates. Annals of Thoracic Surgery, 2016, 101, 1318-1325.	0.7	60
31	Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1146-1153.	2.5	60
32	The Munich Lung Transplant Group: Intraoperative Extracorporeal Circulation in Lung Transplantation. Thoracic and Cardiovascular Surgeon, 2015, 63, 706-714.	0.4	54
33	Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment. Respiratory Medicine, 2019, 153, 44-51.	1.3	54
34	Lung Transplantation for Patients With COVID-19. Chest, 2022, 161, 169-178.	0.4	54
35	Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE). American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1505-1512.	2.5	50
36	The revised GOLD 2017 COPD categorization in relation to comorbidities. Respiratory Medicine, 2018, 134, 79-85.	1.3	45

#	Article	IF	Citations
37	Dupilumab Improves Asthma Control and Lung Function in Patients with Insufficient Outcome During Previous Antibody Therapy. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1177-1185.e4.	2.0	43
38	Impairment of Immunoproteasome Function by Cigarette Smoke and in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 1230-1241.	2.5	42
39	Patient Registries in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 160-167.	2.5	41
40	Outcome of lung transplantation in idiopathic pulmonary fibrosis with previous anti-fibrotic therapy. Journal of Heart and Lung Transplantation, 2018, 37, 268-274.	0.3	40
41	Switching to nintedanib after discontinuation of pirfenidone due to adverse events in IPF. European Respiratory Journal, 2015, 46, 1217-1221.	3.1	38
42	Systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC: a prospective study. Scientific Reports, 2021, 11, 10919.	1.6	37
43	Relationship of hyperlipidemia to comorbidities and lung function in COPD: Results of the COSYCONET cohort. PLoS ONE, 2017, 12, e0177501.	1.1	37
44	Lung volumes predict survival in patients with chronic lung allograft dysfunction. European Respiratory Journal, 2017, 49, 1601315.	3.1	35
45	Uric acid, lung function, physical capacity and exacerbation frequency in patients with COPD: a multi-dimensional approach. Respiratory Research, 2018, 19, 110.	1.4	35
46	Dynamics of SARS-CoV-2 shedding in the respiratory tract depends on the severity of disease in COVID-19 patients. European Respiratory Journal, 2021, 58, 2002724.	3.1	34
47	Evidence for increased SARS-CoV-2 susceptibility and COVID-19 severity related to pre-existing immunity to seasonal coronaviruses. Cell Reports, 2021, 37, 110169.	2.9	34
48	A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis. Chest, 2020, 157, 1506-1512.	0.4	33
49	Acute Effects of Riociguat in Borderline or Manifest Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease. Pulmonary Circulation, 2015, 5, 296-304.	0.8	31
50	Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study. Respiratory Medicine, 2017, 128, 50-56.	1.3	31
51	Pulmonary function impairment of asymptomatic and persistently symptomatic patients 4Âmonths after COVID-19 according to disease severity. Infection, 2022, 50, 157-168.	2.3	31
52	Switch from IL-5 to IL-5-Receptor Î± Antibody Treatment in Severe Eosinophilic Asthma . Journal of Asthma and Allergy, 2020, Volume 13, 605-614.	1.5	30
53	Evidence-based treatment strategies in idiopathic pulmonary fibrosis. European Respiratory Review, 2013, 22, 163-168.	3.0	29
54	Distinct niches within the extracellular matrix dictate fibroblast function in (cell free) 3D lung tissue cultures. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 314, L708-L723.	1.3	28

#	Article	IF	Citations
55	Letermovir for Difficult to Treat Cytomegalovirus Infection in Lung Transplant Recipients. Transplantation, 2020, 104, 410-414.	0.5	28
56	Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study â€“ Rationale and study design. Respiratory Medicine, 2018, 138, 13-20.	1.3	27
57	Collapse phenomenon during Chartis collateral ventilation assessment. European Respiratory Journal, 2016, 47, 1657-1667.	3.1	26
58	Pulmonary CCR2⁺CD4⁺T cells are immune regulatory and attenuate lung fibrosis development. Thorax, 2017, 72, 1007-1020.	2.7	26
59	Effect of COPD severity and comorbidities on the result of the PHQ-9 tool for the diagnosis of depression: results from the COSYCONET cohort study. Respiratory Research, 2019, 20, 30.	1.4	26
60	Pulmonary Glutathione Levels in Acute Episodes of Farmer's Lung. American Journal of Respiratory and Critical Care Medicine, 2000, 161, 1968-1971.	2.5	25
61	Differential response to biologics in a patient with severe asthma and ABPA: a role for dupilumab?. Allergy, Asthma and Clinical Immunology, 2020, 16, 55.	0.9	25
62	Idiopathic Pulmonary Fibrosis in Elderly Patients: Analysis of the INSIGHTS-IPF Observational Study. Frontiers in Medicine, 2020, 7, 601279.	1.2	24
63	Single-cell RNA sequencing reveals ex vivo signatures of SARS-CoV-2-reactive T cells through â€˜reverse phenotypingâ€™. Nature Communications, 2021, 12, 4515.	5.8	23
64	Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months. Journal of Asthma and Allergy, 2021, Volume 14, 863-871.	1.5	23
65	Investigating significant health trends in idiopathic pulmonary fibrosis (INSIGHTS-IPF): rationale, aims and design of a nationwide prospective registry: TableÂ1. BMJ Open Respiratory Research, 2014, 1, e000010.	1.2	22
66	Cell-surface phenotyping identifies CD36 and CD97 as novel markers of fibroblast quiescence in lung fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 315, L682-L696.	1.3	21
67	Short-Term Effects of Comprehensive Pulmonary Rehabilitation and its Maintenance in Patients with Idiopathic Pulmonary Fibrosis: A Randomized Controlled Trial. Journal of Clinical Medicine, 2020, 9, 1567.	1.0	21
68	Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP study. Journal of Heart and Lung Transplantation, 2021, 40, 494-503.	0.3	20
69	Effects of nintedanib by inclusion criteria for progression of interstitial lung disease. European Respiratory Journal, 2022, 59, 2004587.	3.1	19
70	S2K Guideline for Diagnosis of Idiopathic Pulmonary Fibrosis. Respiration, 2021, 100, 238-271.	1.2	19
71	Variability of forced vital capacity in progressive interstitial lung disease: a prospective observational study. Respiratory Research, 2020, 21, 270.	1.4	18
72	Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis. BMJ Open Respiratory Research, 2022, 9, e001310.	1.2	18

#	Article	IF	Citations
73	Recommendations on treatment for IPF. Respiratory Research, 2013, 14, S6.	1.4	16
74	Identification of a novel SERPINA-1 mutation causing alpha-1 antitrypsin deficiency in a patient with severe bronchiectasis and pulmonary embolism. International Journal of COPD, 2015, 10, 891.	0.9	16
75	CAT score single item analysis in patients with COPD: Results from COSYCONET. Respiratory Medicine, 2019, 159, 105810.	1.3	16
76	Pirfenidone exerts beneficial effects in patients with IPF undergoing single lung transplantation. American Journal of Transplantation, 2019, 19, 2358-2365.	2.6	16
77	Pulmonary hypertension in interstitial lung disease: screening, diagnosis and treatment. Current Opinion in Pulmonary Medicine, 2021, 27, 396-404.	1.2	16
78	Realâ€life effectiveness of biological therapies on symptoms in severe asthma with comorbid CRSwNP. Clinical and Translational Allergy, 2021, 11, e12049.	1.4	16
79	Transfer factor for carbon monoxide in patients with COPD and diabetes: results from the German COSYCONET cohort. Respiratory Research, 2017, 18, 14.	1.4	15
80	Idiopathic interstitial pneumonia-associated pulmonary hypertension: A target for therapy?. Respiratory Medicine, 2017, 122, S10-S13.	1.3	15
81	Phenotypic drug screening in a human fibrosis model identified a novel class of antifibrotic therapeutics. Science Advances, 2021, 7, eabb3673.	4.7	15
82	Changes in the current classification of <scp>IIP</scp>: A critical review. Respirology, 2015, 20, 699-704.	1.3	14
83	Surface proteome analysis identifies platelet derived growth factor receptor-alpha as a critical mediator of transforming growth factor-beta-induced collagen secretion. International Journal of Biochemistry and Cell Biology, 2016, 74, 44-59.	1.2	14
84	Proteasome activator PA200 regulates myofibroblast differentiation. Scientific Reports, 2019, 9, 15224.	1.6	14
85	A randomized controlled trial of liposomal cyclosporine A for inhalation in the prevention of bronchiolitis obliterans syndrome following lung transplantation. American Journal of Transplantation, 2022, 22, 222-229.	2.6	14
86	Augmentation of the effects of vasoactive intestinal peptide aerosol on pulmonary hypertension via coapplication of a neutral endopeptidase 24.11 inhibitor. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2015, 308, L563-L568.	1.3	13
87	Impact of Nocturnal Noninvasive Ventilation on Pulmonary Rehabilitation in Patients with End-Stage Lung Disease Awaiting Lung Transplantation. Respiration, 2018, 95, 161-168.	1.2	13
88	Comprehensive clinical profiling of the Gauting locoregional lung adenocarcinoma donors. Cancer Medicine, 2019, 8, 1486-1499.	1.3	13
89	The association of cognitive functioning as measured by the DemTect with functional and clinical characteristics of COPD: results from the COSYCONET cohort. Respiratory Research, 2019, 20, 257.	1.4	13
90	Impact of Education on COPD Severity and All-Cause Mortality in Lifetime Never-Smokers and Longtime Ex-Smokers: Results of the COSYCONET Cohort . International Journal of COPD, 2020, Volume 15, 2787-2798.	0.9	13

#	Article	IF	Citations
91	Molecular Origin of Bloodâ€Based Infrared Spectroscopic Fingerprints**. Angewandte Chemie - International Edition, 2021, 60, 17060-17069.	7.2	13
92	Letermovir in lung transplant recipients with cytomegalovirus infection: A retrospective observational study. American Journal of Transplantation, 2021, 21, 3449-3455.	2.6	12
93	FK506-Binding Protein 11 Is a Novel Plasma Cell-Specific Antibody Folding Catalyst with Increased Expression in Idiopathic Pulmonary Fibrosis. Cells, 2022, 11, 1341.	1.8	12
94	Update in Diffuse Parenchymal Lung Disease 2008. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 439-444.	2.5	11
95	Trip to immunity: resistant cytomegalovirus infection in a lung transplant recipient. International Journal of Infectious Diseases, 2014, 28, 140-142.	1.5	11
96	Residual pulmonary vasodilative reserve predicts outcome in idiopathic pulmonary hypertension. Heart, 2015, 101, 972-976.	1.2	11
97	Cub domain-containing protein 1 negatively regulates TGF-Î² signaling and myofibroblast differentiation. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 314, L695-L707.	1.3	11
98	Relationship of spirometric, body plethysmographic, and diffusing capacity parameters to emphysema scores derived from CT scans. Chronic Respiratory Disease, 2019, 16, 147997231877542.	1.0	11
99	Genomic epidemiology reveals multiple introductions of SARS-CoV-2 followed by community and nosocomial spread, Germany, February to May 2020. Eurosurveillance, 2021, 26, .	3.9	11
100	Lung transplantation in the spotlight: Reasons for high-cost procedures. Journal of Heart and Lung Transplantation, 2016, 35, 1227-1236.	0.3	10
101	Combined Lung and Liver Transplantation With Extracorporeal Membrane Oxygenation Instead of Cardiopulmonary Bypass. Journal of Cardiothoracic and Vascular Anesthesia, 2016, 30, 437-442.	0.6	10
102	Asthma features in severe COPD: Identifying treatable traits. Respiratory Medicine, 2018, 145, 89-94.	1.3	10
103	Adherence To Respiratory And Nonrespiratory Medication In Patients With COPD: Results Of The German COSYCONET Cohort . Patient Preference and Adherence, 2019, Volume 13, 1711-1721.	0.8	10
104	Osimertinib rechallenge under steroid protection following osimertinib-induced pneumonitis: three case studies. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110180.	1.4	10
105	Treating IPFâ€"all or nothing? A PROâ€CON debate. Respirology, 2009, 14, 1072-1081.	1.3	9
106	Evaluation of Short-Term Outcome after Lung Transplantation in the Lung Allocation Score Era. Thoracic and Cardiovascular Surgeon, 2015, 63, 693-698.	0.4	9
107	The natural course of lung function decline in asbestos exposed subjects with pleural plaques and asbestosis. Respiratory Medicine, 2019, 154, 82-85.	1.3	9
108	Treatment of COPD Groups GOLD A and B with Inhaled Corticosteroids in the COSYCONET Cohort â€“ Determinants and Consequences. International Journal of COPD, 2021, Volume 16, 987-998.	0.9	9

#	Article	IF	Citations
109	Gender-specific differences in COPD symptoms and their impact for the diagnosis of cardiac comorbidities. Clinical Research in Cardiology, 2023, 112, 177-186.	1.5	9
110	Activation of immune cell proteasomes in peripheral blood of smokers and COPD patients - implications for therapy. European Respiratory Journal, 2021, , 2101798.	3.1	9
111	Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis. Journal of Heart and Lung Transplantation, 2022, 41, 971-981.	0.3	9
112	High prevalence of falsely declaring nicotine abstinence in lung transplant candidates. PLoS ONE, 2020, 15, e0234808.	1.1	8
113	Impact of the COVID-19 pandemic on the behaviour and health status of patients with COPD: results from the German COPD cohort COSYCONET. ERJ Open Research, 2021, 7, 00242-2021.	1.1	8
114	Management of Acute Exacerbation of Idiopathic Pulmonary Fibrosis in Specialised and Non-specialised ILD Centres Around the World. Frontiers in Medicine, 2021, 8, 699644.	1.2	8
115	Reduced decline of lung diffusing capacity in COPD patients with diabetes and metformin treatment. Scientific Reports, 2022, 12, 1435.	1.6	8
116	Prediction of lung emphysema in COPD by spirometry and clinical symptoms: results from COSYCONET. Respiratory Research, 2021, 22, 242.	1.4	7
117	Response to Letters Regarding Article, â€œAnticoagulation and Survival in Pulmonary Arterial Hypertension: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)â€• Circulation, 2014, 130, e110-2.	1.6	5
118	Deterioration and Mortality Risk of COPD Patients Not Fitting into Standard GOLD Categories: Results of the COSYCONET Cohort. Respiration, 2021, 100, 308-317.	1.2	5
119	Association of CMVâ€špecific Tâ€cell immunity and risk of CMV infection in lung transplant recipients. Clinical Transplantation, 2021, 35, e14294.	0.8	5
120	Daily Routine and Access to Care: Initial Patient Reported Experiences at a German Lung Cancer Center during the COVID-19 Pandemic. Respiration, 2021, 100, 90-92.	1.2	5
121	Lower Prevalence of Osteoporosis in Patients with COPD Taking Anti-Inflammatory Compounds for the Treatment of Diabetes: Results from COSYCONET. International Journal of COPD, 2021, Volume 16, 3189-3199.	0.9	5
122	Inhaled Treprostinil in Pulmonary Hypertension in the Context of Interstitial Lung Disease: A Success, Finally. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 144-145.	2.5	5
123	Riociguat in Patients with CTEPH and Advanced Age and/or Comorbidities. Journal of Clinical Medicine, 2022, 11, 1084.	1.0	5
124	Heterogeneous pattern of differences in respiratory parameters between elderly with either good or poor FEV1. BMC Pulmonary Medicine, 2018, 18, 27.	0.8	4
125	Relationship between clinical and radiological signs of bronchiectasis in COPD patients: Results from COSYCONET. Respiratory Medicine, 2020, 172, 106117.	1.3	4
126	Perception of climate change in patients with chronic lung disease. PLoS ONE, 2017, 12, e0186632.	1.1	4

#	Article	IF	Citations
127	Dynamics of urinary and respiratory shedding of Severe acute respiratory syndrome virus 2 (SARS-CoV-2) RNA excludes urine as a relevant source of viral transmission. Infection, 2022, 50, 635-642.	2.3	4
128	Polyomavirus exerts detrimental effects on renal function in patients after lung transplantation. Journal of Clinical Virology, 2021, 145, 105029.	1.6	4
129	The Role of Thoracic Surgery in Small Cell Lung Cancer â€“ A Large Longitudinal Analysis (2002-2015) Based on Real-World Data. Clinical Lung Cancer, 2022, 23, 244-252.	1.1	4
130	Combined diffusing capacity for nitric oxide and carbon monoxide as predictor of bronchiolitis obliterans syndrome following lung transplantation. Respiratory Research, 2018, 19, 171.	1.4	3
131	Safety and Efficacy of Steroid Pulse Therapy for Acute Loss of FEV1 in Lung Transplant Recipients After Exclusion of Acute Cellular Rejection. Transplantation Proceedings, 2020, 52, 309-314.	0.3	3
132	Automated quantitative thin slice volumetric low dose CT analysis predicts disease severity in COVID-19 patients. Clinical Imaging, 2021, 79, 96-101.	0.8	2
133	Oxygenated Hemoglobin Predicts Outcome in Patients with Chronic Lung Allograft Dysfunction. Respiration, 2022, 101, 638-645.	1.2	2
134	Subtle signs â€“ red flags. European Respiratory Journal, 2020, 55, 2000606.	3.1	1
135	Ambrisentan: a guide to its use in pulmonary arterial hypertension classified as WHO functional class II or III. Drugs and Therapy Perspectives, 2011, 27, 1-8.	0.3	0
136	Ambrisentan: a guide to its use in pulmonary arterial hypertension in the EU. Drugs and Therapy Perspectives, 2014, 30, 231-240.	0.3	0
137	Ambrisentan in pulmonary arterial hypertension: a guide to its use in the EU. Drugs and Therapy Perspectives, 2016, 32, 50-59.	0.3	0
138	Ambrisentanâ€‰Â±â€‰tadalafil in WHO functional class II/III pulmonary arterial hypertension: a guide to its use in the EU. Drugs and Therapy Perspectives, 2018, 34, 289-299.	0.3	0
139	Daily Chronic Intermittent Hypobaric Hypoxia Does Not Induce Chronic Increase in Pulmonary Arterial Pressure Assessed by Echocardiography. Canadian Respiratory Journal, 2018, 2018, 1-8.	0.8	0
140	Reply to Sanyal et al.: Overlooked Role of Histopathology in Evaluations for Occupational/Environmental Exposures. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1581-1583.	2.5	0
141	Reply: Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis. European Respiratory Journal, 2021, 57, 2100283.	3.1	0
142	Molecular Origin of Bloodâ€Based Infrared Spectroscopic Fingerprints**. Angewandte Chemie, 2021, 133, 17197-17206.	1.6	0
143	InnenrÃ¼cktitelbild: Molecular Origin of Bloodâ€Based Infrared Spectroscopic Fingerprints (Angew.) Tj ETQq1 1 0.784314 rgBT /Ove	1.6	0
144	A New Tool to Assess Quality of Life in Patients with Idiopathic Pulmonary Fibrosis or Non-specific Interstitial Pneumonia. Pneumologie, 2022, 76, 25-34.	0.1	0

#	Article	IF	Citations
145	Lymphocytes and sinus histiocytosis in tumor and matched lymph nodes as predictors of survival in non-small-cell lung cancer. Future Oncology, 2022, 18, 481-489.	1.1	0
146	High prevalence of falsely declaring nicotine abstinence in lung transplant candidates. , 2020, 15, e0234808.		0
147	High prevalence of falsely declaring nicotine abstinence in lung transplant candidates. , 2020, 15, e0234808.		0
148	High prevalence of falsely declaring nicotine abstinence in lung transplant candidates. , 2020, 15, e0234808.		0
149	High prevalence of falsely declaring nicotine abstinence in lung transplant candidates. , 2020, 15, e0234808.		0
150	High prevalence of falsely declaring nicotine abstinence in lung transplant candidates. , 2020, 15, e0234808.		0
151	High prevalence of falsely declaring nicotine abstinence in lung transplant candidates. , 2020, 15, e0234808.		0